Pharmaceuticals Hazardous

Special attention to safety requirements is necessary when performing site inspections. These include aspects in relation to the dosage form and activities observed (e.g. radioactive pharmaceuticals, hazardous materials, laboratory reagents, equipment and apparatus, explosions, personnel lifts, ladders, glassware, freezers, steam, radiation, microbiological hazards, viral and biological products and waste, and other relevant possible hazards). 

Polyisobutylene and isobutylene—isoprene copolymers are considered to have no chronic hazard associated with exposure under normal industrial use. Some grades can be used in chewing-gum base, and are regulated by the PDA in 21 CPR 172.615. Vulcanized products prepared from butyl mbber or halogenated butyl mbber contain small amounts of toxic materials as a result of the particular vulcanization chemistry. Although many vulcanizates are inert, eg, zinc oxide cured chlorobutyl is used extensively in pharmaceutical stoppers, specific recommendations should be sought from suppHers. 

Applications Deep-well injection has been used principally for liquid wastes that are difficult to treat and dispose of by more conventional methods and for hazardous wastes. Chemical, petrochemical, and pharmaceutical wastes are those most commonly disposed of with this method. The waste may be liquid, gases, or solids. The gases and solids are either dissolved in the liquid or are carried along with the liquid. 

Control of metalloid content in natural objects, foodstuff and pharmaceuticals is an important task for modern analytical chemistry. Determination of elements such as Arsenic is necessary for evaluation of object toxicity, since their content in environment may exceed MCL (maximum contaminant level), posing hazard to human health. Elements such as Selenium in definite doses are healthy, but in greater quantities they produce toxic effect. 

Both parties need to identify responsibilities for choosing the right equipment for the process, preparing equipment for the process, and decontaminating equipment. Consider whether chemical and process hazards have been addressed in the selection, preparation, and decontamination of equipment. Examine the need to contractually address containment and disposal of residual process fluids and decontamination materials. If food products or pharmaceuticals are involved, cleaning methods may also be an issue to address in the contract. 

The control of chemical reactions (e.g., esterification, sulfonation, nitration, alkylation, polymerization, oxidation, reduction, halogenation) and associated hazards are an essential aspect of chemical manufacture in the CPI. The industries manufacture nearly all their products, such as inorganic, organic, agricultural, polymers, and pharmaceuticals, through the control of reactive chemicals. The reactions that occur are generally without incident. Barton and Nolan [1] examined exothermic runaway incidents and found that the principal causes were ... 

About two-thirds of the N2 produced industrially is supplied as a gas, mainly in pipes but also in cylinders under pressure. The remaining one-third is supplied as liquid N2 since this is also a very convenient source of the dry gas. The main use is as an inert atmosphere in the iron and steel industry and in many other metallurgical and chemical processes where the presence of air would involve fire or explosion hazards or unacceptable oxidation of products. Thus, it is extensively used as a purge in petrochemical reactors and other chemical equipment, as an inert diluent for chemicals, and in the float glass process to prevent oxidation of the molten tin (p. 370). It is also used as a blanketing gas in the electronics industry, in the packaging of processed foods and pharmaceuticals, and to pressurize electric cables, telephone wires, and inflatable rubber tyres, etc. 

For food and drink, medical, pharmaceuticals and cosmetics production the microbiological quality of the water becomes paramount. Even in applications where biological quality is not directly important, uncontrolled growth can be a damaging nuisance. Warm-water systems and cooling circuits in particular are a potential hazard (e.g. from Legionella). Some water treatment or conditioning is commonly required. 

Few reactions are completely clean in the sense of giving only the desired product. There are some cases where the side products have commensurate value with the main products, but these cases are becoming increasingly rare, even in the traditional chemical industry, and are essentially nonexistent in fields like pharmaceuticals. Sometimes, C is a hazardous waste and has a large, negative value. 

Since full analyses are carried out, a lot of data are generated. Every parameter is reviewed for trends that signal product aging or outright decomposition of the active principle this can be as cosmetic in nature as discoloration or as potentially hazardous as buildup of toxic derivatives. If the drug substance is an ester, for example, hydrolysis, particularly if moisture penetrates the primary packaging material, will decompose the compound into its acid and alcohol components. From a pharmaceutical or medical viewpoint, even if there is no toxicity issue involved, this will result in a loss of bioavailability. Even this is to be avoided because subpotency introduces therapeutic uncertainty and can go as far as lethal undertreatment. 

The hazard of the transfer of microorganisms from humans to pharmaceutical preparations may be reduced by comprehensive training in personal hygiene coupled with regular medical checks to prevent carriers of pathogenic organisms from coming in contact with any product. 

Rules and Guidance for Pharmaceutical Manufacturers and Distributors (1997) London HMSO. Spooner D.F. (1996) Hazards associated with the microbiological contamination of cosmetics, toiletries andnon-sterile pharmaceuticals. Iw.Microhial Quality Assurance in Cosmetics, Toiletries andNon-sterile Pharmaceuticals, 2nd edn (eds R.M. Baird S.F. Bloomfield), pp. 9-27. London Taylor Francis. 

We now illustrate the opposite case where the intermediate is in fact a highly undesirable substance, as it presents a health, or even explosion, hazard. The hydrogenation of aromatic nitro compounds, such as the one shown in Fig. 2.6, is industrially important for the production of dyes, whiteners, agrochemicals and pharmaceuticals. The reaction occurs in the presence of a platinum catalyst and proceeds via intermediates, among which the hydroxylamine (-NHOH) species is particularly hazardous, as it is both carcinogenic and explosive. Unfortunately, standard platinum catalysts give rise to high levels of this undesired intermediate. 

The pharmacology and toxicology of certain economic poisons have been developed to a degree which surpasses investigations of any other class of nonmedicinal compounds. In certain instances more is known concerning the site and mechanism of action, the absorption, distribution, and excretion of these substances than is known concerning some of the more commonly used pharmaceutical compounds. This has come about as a result of the conscientious recognition of the public health hazards which are inherent in the economic poisons. 

The potential for a compound to induce carcinogenicity is a crucial consideration when establishing hazard and risk assessment of chemicals and pharmaceuticals in humans [53]. To date, the standard approach to assess carcinogenicity at a regulatory level is the 2-year bioassay in rodents. According to the recent REACH... 

In a study of explosive potential of 20 pharmaceutical products, Chloramine B was found to present the greatest fire hazard, decomposing explosively at 185°C. 

What distinguishes the pharmaceutical market and justifies the need to fix maximum limits to public financing such as those involved in RP systems The pharmaceutical sector differs from other sectors in veiy important respects,14 15 including an imperfect agency relationship, imperfect informa -tion, moral hazard and joint, sunk and fixed costs. 

Insurance Coverage of Pharmaceuticals, Use, Moral Hazard and Efficiency. Effects of Co-payment... 

This welfare loss implies inefficiency. Moral hazard gives rise to an inefficient reallocation of consumption, channelling it towards pharmaceuticals and away from other goods and services, both health care and others, which are not covered by insurance. Preventive services - sport, nutrition - become underused. 

If we say, for example, that it stands at -0.2, we mean that if the price rises by 1 per cent, the quantity demanded will decrease by 0.2 per cent. In fact, the price elasticity of demand measures the potential for moral hazard.9 In Figure 7.1, the slope of the demand function for 100 per cent copayment is what ultimately determines the shaded area, which as we already know, corresponds to the welfare loss of total coverage pharmaceutical insurance. 

---